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Histamine has been postulated as an important factor in a number 
of physiological processes (10), such as fetal growth, wound healing, 
the synthesis of granuolcytes in bone marrow, mediation of microcir¬ 
culation (27) and hormone action (31), and gastric acid secretion (15). 
It is also thought th play a role in a number of pathological states 
(3), such as anaphalaxis, myelogenous leukemia, mastocytosis (16), 
Zollinger-Ellison syndrome (15), thyrotoxicosis, periarteritis nodosa, 
asthma, hay fever (25), and peptic ulcer (4). As an increased level 
of histamine has been noted in many of these situations, it is under¬ 
standable that interest would be focused on the enzyme responsible 
for synthesis of histamine, histidine decarboxylase, and on any 
inhibitors of this enzyme. In this thesis the present knowledge 
concerning histidine decarboxylase, methods for assay of the enzyme, 
and agents that inhibit it will be surveyed briefly. Also, as back¬ 
ground for the studies performed, certain physiological aspects of 
histamine with emphasis on its proposed role in gastric acid secretion 
will be discussed. The experimental section of this thesis is concerned 
. 
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with the development of a technique for assay of histidine decarb¬ 
oxylase inhibitors in plasma. The drugs studied were the hydrazino 
analog of histidine (MK-785), and 4-bromo-3-hydroxybenzyloxyamine 
(brocresine). 
The first approach to the problem that was attempted was based 
on a report by Krauss, e_t aj,.(13). The authors, choosing patients 
with disease states in which leukocytes had higher than normal levels 
of histidine decarboxylase, detected decreased levels of both histamine 
and histidine decarboxylase activity in the granulocytes from patients 
with chronic myelogenous leukemia after administration of brocresine. 
An attempt was made to use the histamine level in granulocytes of 
normal volunteers as an index of histidine decarboxylase inhibition 
in the plasma. Unfortunately, the amount of blood needed to detect 
histamine in the white cell fraction was impractical, and consistent 
levels could not be detected with 100 cc of blood, so this approach 
was abandoned. 
The next approach to the problem proved successful. A radioisotopic 
assay for histidine decarboxylase activity previously described by 
Levine and Watts (19) was adapted so as to accurately assay histidine 
decarboxylase inhibition in as little as 5 cc of human blood. The 
experimental section of this thesis describes this assay as well as 
the results obtained by application of this assay in both man and rat. 
In the human studies known concentrations of both MK-785 and brocresine 
in pooled human plasma were assayed _in vitro and curves were constructed 
from which values from subsequent _in vivo studies could be expressed 
as actual concentrations of the drug. Next, the plasma levels of both 
' 
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MK-785 and brocresine were determined at various time intervals 
after various peroral doses of the two drugs. From this, dose-response 
curves were constructed showing actual plasma concentration of the 
drugs with respect to time after administration. In the rat, intra- 
peritoneal doses of MK-785 and brocresine were correlated both with 
the plasma level of the drugs and the level of histidine decarboxylase 
inhibition in stomach tissue. 
The data from these studies allow a number of conclusions and 
correlations to be made. The studies done in humans provide information 
concerning rate of absorbtion and clearance of MK-785 and brocresine 
after various oral doses, and plasma concentration levels reached with 
these oral doses. The studies done in rats provide data concerning 
inhibition of histidine decarboxylase in tissue and correlation of 
this inhibition with concurrent plasma levels of the drugs. Presuming 
that the relationships between plasma levels and enzyme inhibition 
exist in man as were demonstrated in rats, the dose-response curves 
which resulted from the human studies are useful in the development 
of clinical dosage schedules. 
REVIEW 
Histamine is synthesized in mammalian tissue by decarboxylation 
of its precursor amino acid, histidine. This is accomplished by a 
specific histidine decarboxylase. Although histidine is also decarb- 
oxylated _in vitro by a non-specific aromatic L-amino acid decarboxylase, 
it is generally concluded that only the specific histidine decarb¬ 
oxylase functions in vivo to synthesize histamine (17). This conclusion 
- 
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is based in part on the low affinity of the non-specific decarb¬ 
oxylase for histidine (22). Furthermore, specific inhibitors of the 
specific histidine decarboxylase, such as a-methyl histidine (10), 
decrease histamine levels in tissue and urine of rats, whereas 
administration of a selective inhibitor of the non-specific decarb¬ 
oxylase, a-methyl dopa (10,17), has no effect on either urinary or 
tissue histamine levies. The enzyme, histidine decarboxylase, is 
specific for the substrate histidine (5-8), requires pyridoxal-5*- 
phosphate as a cofactor (5,6), has a pH optimum which varies inversely 
with substrate concentration (from pH of 6.2 for 5 x 10m histidine 
to pH of 7.2 with 5 x 10“6 m substrate) (5,6,7), and a Km which 
varies inversely with pH (pKm is 1.5 at pH of 4.0, pKm is 5.5 at 
pH of 9.0) (1,7), On the basis of these data, although the enzyme is 
more active at acid pH values, it is thought to interact only with 
the anionic form of histidine as substrate, an ionic species which 
is more abundant in alkaline media. 
The structural formulas of the two histidine decarboxylase 
inhibitors used in the following studies, MK-785 and brocresine, 
are shown in Figure 1. MK-785, the hydrazine analog of the substrate 
histidine, functions as a reversible (19) competitive inhibitor by 
interacting with the cofactor pyridoxal phosphate. In vivo, MK-785 
is a more potent inhibitor of histidine decarboxylase than of aromatic 
L-amino acid decarboxylase, whereas brocresine strongly inhibits both 
enzymes. By contrast brocresine (4-bromo-3-hydroxybenzyloxyamine) 
appears to function as a competitive irreversible (19) inhibitor 
by forming an oxime by reaction with the cofactor and then complexing 
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with the enzyme (21); this oxime has been shown to be a non-compet¬ 
itive inhibitor of the reaction (21). 
Several procedures are available to assay histidine decarboxylase 
activity _in vitro; these are compared by Maudsley, et a_l.(23) . 
Selection of an assay procedure is a controversial issue; some 
investigators do not accept results of an assay other than their 
own. Oneof the controversial points is the preparation of tissue. 
Some assays use intact cells, obtaining results which differ from 
those studies in which cell-free homogenates are used (10). Furthermore, 
some assays use a nitrogen atmosphere, which may or may not affect 
enzyme activity (1). 
In assays where the tissue is homogenized, the supernatant is at 
times purified by gel filtration, ammonium sulfate precipitation 
or dialysis to remove endogenous activators, inhibitors and cofactors. 
It is easy to see that variation in these techniques might quite 
easily lead to variable results. The means of detection of histidine 
decarboxylase activity is another variable facet of these assays. 
Nonisotopic methods are usually too insensitive to detect the amount 
of enzyme present in most tissues studied. Of the two isotopic methods 
in wide use, ring labeled histidine as substrate, in which the 
product is a histamine derivative, is the more highly specific 
but more time consuming method. A simpler method, and the basis of the 
assay used in this study, uses histidine labeled in the carboxyl 
carbon; enzyme activity is measured by the trapping of the evolved 
in hydroxide of hyamine for subsequent scintillation counting. 
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The problems in this method primarily involve high blank values 
due to nonenzymatic decarboxylation in the reaction mixture. Since 
this method employs a stomach homogenate in the reaction mixture 
which is not purified further by differential precipitation or gel 
filtration, it may contain substances which either inhibit or enhance 
the enzyme reaction. Although substantial time has been devoted to 
the development of a valid blank, this problem has not yet been 
solved, and contributes to the variability in parts of the present 
study. Certain steps, such as heating the substrate prior to use, 
have given reasonably valid blank values. In summary, the variation 
in tissue preparation as well as in the product detection method in 
the various assays of histidine decarboxylase is a controversial area 
which is not yet resolved. The method used in these studies is not 
as highly specific as those methods based on ring labeled histidine 
,however it is specific, highly sensitive and rapid, and is adaptable 
to a number of clinical and laboratory situations. 
As previously mentioned, histamine is thought to be a significant 
factor in a variety of physiological and pathological states (8,10). 
High histidine decarboxylase activity has been found in relation to 
many of these states, such as in fetal tissues, granulation tissue, 
some tumors and the gastric mucosa of many animals and man. The 
relationships of histamine and histidine decarboxylase activity in 
the gastric mucosa to gastric acid secretion in the rat have been 
studied in detail by several investigators. The rat gastric mucosa 
contains a large rapidly turning over pool of histamine (12,30) which 
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is released by a number of agents (9,29) which are known to stimulate 
gastric acid secretion. Soon after histamine and acid release, there 
is an increase in histidine decarboxylase activity in the gastric 
mucosa (10-12,26,30). The fact that the rat stomach contains a 
rapidly turning over pool of histamine and that histamine appears 
to be a mediator of gastric acid secretion in this aminal (2) makes 
this an opportune area for the study of histidine decarboxylase 
inhibitors. Treatment of rats with either MK-785 or brocresine 
results in decreased acid production both in basal states and following 
gastrin stimulation (14), as well as a significant decrease in stress 
ulcer formation in response to cold and restraint (18,28). In these 
studies gastric acid secretion occurred in response to administered 
histamine, indicating functioning acid secreting cells and not merely 
nonspecific destruction of cellular function by the inhibitors (18). 
The above finding tend to strongly implicate histamine as a mediator 
in gastric acid secretion in the rat (2). Extrapolation of this 
concept to primates and man was a dubious jump due to the inability 
to clearly demonstrate specific histidine decarboxylase in the gastric 
mucosa of species other than the rat (11). Recently, however, significant 
specific Wistidine decarboxylase activity has been domonstrated in the 
gastric mucosa of man as well as other primates (24). Furthermore, 
clinical trials using brocresine in patients with Zollinger-Ellison 
syndrome, a disease characterized by gastric hypersecretion secondary 
to a gastrin-like substance elaborated by a non-beta cell tumor of the 
pancreas, demonstrated a decrease in urinary histamine excretion and 
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and symptomatic relief while on histidine decarboxylase inhibitors (15). 
These recent findings point toward histamine as a mediator of gastric 
acid secretion in man as well as the rat. Availability of detailed 
investigations on rat stomach suggested this organ as the system in 
which to study the correlation of plasma inhibitor levels with tissue 
histidine decarboxylase inhibition. 
EXPERIMENTAL 
Although several methods are available to assay histidine decarb¬ 
oxylase activity _in vitro,at the onset of these studies there were 
no methods available to assay plasma levels of histidine decarboxylase 
inhibitors or to correlate drug dosage with plasma level or tissue 
activity. As clinical trials (16,25,26) had already begun with two 
histidine decarboxylase inhibitors, MK-785 and brocresine, it appeared 
important to develop a rapid and sensitive assay which could be 
applied to any inhibitor of histidine decarboxylase, which required 
small amounts of blood in order to allow detailed dose-response curves 
to be constructed, and which could be used easily in clinical situations. 
Therefore a rapid assay was developed based upon estimation of the 
power of plasma to inhibit histidine decarboxylase activity after 
administration of a drug. This approach to the assay of drug levels was 
chosen because some histidine decarboxylase inhibitors, such as bro¬ 
cresine, are so potent that concentrations as low as 0.05 pM in plasma 
produce significant inhibition, and compounds at this concentration 
would probably defy detection by ordinary chemical means. However, a 
.. 
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method based upon histidine decarboxylase inhibition should be 
generally applicable to assay of plasma levels of any histidine 
decarboxylase inhibitor. 
This method was applied to the study of plasma levels of MK-785 
and brocresine after peroral administration of single doses to 
normal subjects, and to the study of plasma levels of rats after 
single intraperitoneal doses of either of the two inhibitors. The 
assay was modified to allow estimation of histidine decarboxylase 
activity in rat stomach tissue after single intraperitoneal doses 
of MK-785 or brocresine. Rat studies were performed to determine the 
correlation, if any, between plasma levels and tissue activity of 
the two histidine decarboxylase inhibitors. Dose-response curves in 
man permitted comparison between the two systems and allowed the 
relationship between plasma drug levels and tissue activity observed 
to be tentatively extrapolated to man. 
MATERIALS AND METHODS 
The two drugs used throughout this study are D-2-hydrazine-3- 
4(5)-imidazole proprionic acid (MK-785) supplied as a powder for 
use in the rat or as 50 mg. capsules for human use by Merck Institute 
for Therapeutic Research, and 4-bromo-3-hydroxybenzyloxyamine 
(brocresine), supplied as a powder or in 50 mg. and 200 mg. capsules 
by Lederle Laboratories. 
Studies in man. Histidine decarboxylase was prepared from whole 
fetal rats (19 to 20 days gestation) by a modification (19) of the 
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method of Hakanson (6) in which homogenization of the fetal rats in 
pH 5.5 sodium acetate buffer was followed by differential precip¬ 
itation of the crude mixture. Further purification was effected by 
dialysis. The enzyme preparation was stored at -20° C. until used 
for assay. Assay of histidine decarboxylase inhibition was performed 
by a modification of a previously described method (19). This method 
is based upon determination of the power of plasma from subjects 
who have ingested either MK-785 or brocresine to inhibit the activity 
of a preparation of histidine decarboxylase _in vitro. The method 
employs incubation of the enzyme with histidine (labeled in the 
carboxyl carbon) in the presence of excess co-factor, and trapping 
the evolved in hyamine hydroxide for assay in a Packard "Tri- 
Carb" scintillation spectrometer. The incubation vials contained, in 
addition to excess co-factor, histidine, and histidine decarb¬ 
oxylase, 0.8 cc human plasma, sodium phosphate buffer in order to 
maintain the incubation mixture at a pH of 6.8, and streptomycin 
sulfate, added to supress the growth of any bacteria which may 
decarboxylate histidine. In these experiments incubations were done in 
final volumes of 2.0 ml. Blanks consisted of complete incubation 
mixtures to which brocresine was added to a final comcentration of 
0.1 pM and 0.8 cc water was substituted for human plasma. 
Plasma from some subjects who had received no drug was found to 
produce small degrees of histidine decarboxylase inhibition; this 
inhibition was generally small (0-10%) but in some cases was greater. 
In these experiments this inhibition was equated to zero by designating 
. 
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the control (pretreatment) value for any subject as zero percent 
inhibition. 
The subjects of these studies were 27 normal volunteers, ages 
20 to 46, of which 14 were white females, two, negro females, and 
eleven, white males. Venous blood was aspirated into 10 ml. heparin¬ 
ized Vacutainer (r) tubes (3200 KA) before and at various times 
after ingestion of the drug. Plasma was separated by centrifugation 
and stored at -20° C. until assay. 
Studies in the rat. Female CD rats (derived origionally from 
Sprague-Dawley stock) were purchased from Charles River Laboratories, 
North Wilmington, Massachusetts. At the time of study they weighed 
between 140 and 180 g. In the studies determining the plasma levels 
of the two drugs with respect to time post injection, approximately 
ten rats were used for each point. Each rat was given a dose of 150 
mg./kg. of either MK-785 or brocresine intraperitoneally. The rats 
were sacrificed either at five, 15, or 30 minutes or at one, two, 
four, eight or 16 hours after injection. Blood was obtained by cardiac 
puncture and aspiration into an heparinized syringe and 0.8 ml. 
plasma was assayed for histidine decarboxylase inhibitory activity 
by the method described in the human study. 
In studies correlating inhibition of histidine decarboxylase 
activity in stomach tissue with elapsed time after injection of the 
drug, ten rats were used for each point: seven experimental and three 
controls. A similar protocol was followed with respect to the dose 
and the time intervals used. Controls were injected with normal saline. 
All rats were injected and left in their cages in the Animal Care 
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Division with free access to food and water until sacfificed. Stomachs 
were trimmed, washed and blotted dry prior to assay for histidine 
decarboxylase activity as described by Levine and Watts (19). The 
method differs from the assay described previously in human studies 
in that 0,8 cc stomach homogenate was used in place of human plasma, 
while purified fetal rat histidine decarboxylase was not added to the 
incubation mixture. Protein in the stomach tissue was measured by 
a modification of the phenol reagent method (26). Histidine decarb¬ 
oxylase activity was expressed as counts/min./mg. protein. 
RESULTS 
Studies in man. In preliminary experiments, MK-785 and brocresine 
were dissolved in pooled human plasma; serial dilutions were made 
by addition of plasma. Inhibition of histidine decarboxylase activity 
by drugs dissolved in plasma _in vitro is illustrated in Figures 2 and 
3. For MK-785, histidine decarboxylase inhibition was a linear 
logarthmic function of drug concentration in plasma over a range of 
0.1 to 100 pM. For brocresine the range of concentration that could 
be studied reliably was smaller, ranging from 0.1 to 1.0 pM. These 
curves were used to standardize subsequent studies on plasma levies 
of histidine decarboxylase inhibitors _in vivo. 
Figures 4 and 5 illustrate plasma levels of MK-785 and brocresine 
resulting from oral administration of single doses. These figures 
illustrate that the plasma levels obtained with oral administration 
of these drugs varies substantially between subjects. This variation 
was more striking with MK-785 than with brocresine. 
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Figures 6 and 7 illustrate plasma levels of MK-785 and brocresine 
after oral administration of various doses. Again differences between 
subjects were noted. These studies revealed some major differences 
between the two inhibitors. Peak plasma levels of MK-785 were much 
higher than those obtained with equal doses of brocresine. For 
example, after an oral dose of 50 mg. of MK-785, plasma levels reached 
a peak of 0.5 to 0.6 pM while double that dose of brocresine produced 
plasma levels that were barely detectable. Peak levels in plasma were 
reached much earlier with brocresine (30 to 45 minutes) than with 
MK-785 (two to four hours). Also, it was apparent that brocresine 
disappeared from plasma much more rapidly than did MK-785. 
Studies in the rat. Data from determination of plasma levels of 
both MK-785 and brocresine at various times after parenteral admin¬ 
istration are shown in Figures 8 and 9. P^esults are plotted semi- 
logarithmically as a ratio of the average control value and the 
average experimental value; high numbers indicate greater concentration 
of histidine decarboxylase inhibitors in the plasma. MK-785, as shown 
in Figure 8, reaches peak levels in one hour, and maintains fairly 
high levels for our hours. Brocresine, however, reaches its peak 
plasma level in about 15 minutes and is essentially cleared from the 
blood within one hour. 
The relationship of histidine decarboxylase activity in stomach 
tissue to time elapsed after parenteral injection of either MK-785 
or brocresine is shown in Figures 10 and 11. Individual values, 
originally expressed as counts/min./mg. protein, were converted to 
percent inhibition. Blank values in this study were not subtracted 
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from experimental values.* While this leads to a less dramatic 
curve of histidine decarboxylase inhibition in stomach tissue, it 
indicates the time course of drug activity in the tissue and also 
points out some of the problems previously mentioned concerning the 
assay when applied to tissue having low enzyme activity. In Figure 
10 it can be seen that histidine decarboxylase in the stomach is 
highly inhibited between 15 minutes and four hours after injuction 
of MK-785, but enzyme activity returns to normal after ten hours. 
In contrast, brocresine (Figure 11) inhibits gastric histidine 
decarboxylase activity maximally between 30 minutes and two hours, 






described above indicate the feasability of 
decarboxylase inhibitor levels in plasma by 
inhibiting potency of plasma after drug admin- 
* Frequently blank values were higher than experimental points 
supposedly representing high histidine decarboxylase inhibition. 
This was probably due to various substances in stomach homogenates 
which either enhanced or inhibited the decarboxylation reaction but 
were not represented in a blank which contained only water and 
buffered solution as substitute for the homogenates. 
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istration. This constitutes the first report of a method for assay 
of these agents in plasma. Reasons for development of this technique 
and the particular advantage of its general applicability have been 
commented on earlier. However, the assay is not specific for any 
given reagent but will reflect the presence of all chemical or 
metabolic derivatives that inhibit histidine decarboxylase. 
Comparison of drug plasma curves of either MK-785 or brocresine 
in man and in the rat will show that they behave similarily in both 
species. In man, MK-785 maintains high plasma levels for about eight 
hours with 400 mg. doses; with 200 mg. doses, plasma levels were 
significantly decreased after eight hours, closely resembling effects 
in the rat. Brocresine in man maintains peak levels only for 30 minutes 
to one hour, with significant decrease by two hours. The concentration 
curve of the drug in rat plasma, after parenteral administration 
shows even more rapid clearance, but in general is similar. Comparison 
of the plasma curves with tissue activity in the rat seems to demonstrate 
rapid equlibrium between plasma and tissue for the two drugs, with 
histidine decarboxylase inhibition demonstrable for only one to three 
hours after the drug is cleared for the plasma. This is consistant, in 
the case of a proposed irreversible inhibitor such as brocresine, with 
enzyme half lives of 100 (12) to 120 (30) minutes in the rat gastric 
mucosa. The data suggest that brocresine is absorbed rapidly and 
equilibrates rapidly with gastric tissue; the length of demonstrable 
histidine decarboxylase inhibition appears to be a function of resyn¬ 
thesis of the enzyme after irreversible inhibition. Brocresine itself 
is cleared from rat plasma after two hours and is probably also absent 
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from gastric mucosa equally soon. Studies of MK-785, thought to be 
a reversible inhibitor, were less precise and may merely reflect 
clearance of the drug from plasma and tissues after several hours. 
Recovery from this type of inhibition should not be dependent on 
synthesis of new enzyme. 
That brocresine is cleared from the plasma in three hours in man 
does not necessarily indicate that it has been cleared from the body. 
But the rat studies suggest that tissue levels of these histidine 
decarboxylase inhibitors parallels plasma levels with a residual 
inhibitory phase of a few hours, and perhaps a similar relationship 
holds in man. Until further data are available, the assumption that 
maximum plasma levels may parallel maximum enzyme inhibition in some 
tissues may serve as a guide in construction of dosage schedules. 
Before this new this new technique became available, several studies 
using brocresine were in progress in both normal subjects and in 
patients with various diseases. Doses used in these studies were either 
200 or 400 mg. every eight hours. The present studies indicate that, 
although the doses were sufficiently large, administration was too 
imfrequent to maintain effective plasma concentrations of the drug. 
When the frequency of administration was changed to every four hours, 
clinical results were improved (20,25). Thus the data presented here 
should be of value in future clinical trials with MK-785 and brocresine, 
and the availability of this method to assay plasma levels of any 
histidine decarboxylase inhibitor should prove to be a useful adjunct 




A technique for the assay of plasma levels of histidine decarb¬ 
oxylase inhibitors in man has been described. The assay is based 
upon plasma inhibition of histidine decarboxylase activity _in vitro 
after drug administration. This method was used to study plasma 
levels of MK-785 and brocresine after administration of various 
doses in both man and rat. A similar assay, described previously, 
was used to estimate histidine decarboxylase activity in rat gastric 
mucosa after inratperitoneal injection of either drug. 
Correlations between plasma levels and gastric tissue enzyme 
inhibition were found, and tentative conclusions were made regarding 
similar relationships in man. Based on our results, alterations 
were made in dosage schedules in clinical trials using brocresine. 
The assay technique described should prove useful in future clinical 
trials with either MK-785 or brocresine, and should be generally 










Figure 1. Structural formulas of the two histidine decarboxylase 
inhibitors used in this study. 
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Figure 2. Inhibition of histidine decarboxylase activity by MK-785 
dissolved in plasma _in vitro. The concentration designated 
on the abcissa is the concentration of MK-785 in plasma, 
of which 0.8 ml. was added to the incubation mixture to a 
final volume of 2.0 ml. 
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Figure 3. Inhibition of histidine decarboxylase activity by brocresine 
dissolved in plasma _in vitro. The concentration designated 
on the abcissa is the concentration of brocresine in plasma, 
of which 0.8 ml. was added to the incubation mixture to a 





















Figure 4. Concentrations of MK-785 in plasma of six individuals at 
various times after oral administration of a single dose 
of 200 mg. at zero time. 
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Figure 5. Concentrations of brocresine in plasma of five individuals 
at various times after oral administration of a single dose 




















Figure 6. Plasma levels of MK-785 at various times after oral 
administration of various single doses. The data are 
plotted as mean concentrations in all subjects studied. 
At those points at which results are available from three 
or more individuals, there are vertical brackets indicating 
mean deviations (sum of deviations from the mean divided 



















Figure 7. Plasma levels of brocresine at various times after oral 
administration of various single doses. The data are 








Figure 8. Plasma levels of MK-785 in the rat at various times after 
intraperitoneal administration of a single dose of 150 mg./ 
kg. at zero time. Brackets indicate ± one standard deviation. 
The values on the abcissa indicate the ratio of the average 
control value divided by the average experimental value. 




























Igure 9. Plasma levels of brocresine in the rat at various 
times after intraperltoneal administration of a single 
l^Fl^reT tlnie' ^ d°Sa8e data are Plotted as 
>'♦ $+ /> jtKPir P* .r «I » ' >-•«-** '■••• -u.* J 
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